Flowerkist Skin Care & Cosmetics Inc
Flowerkist Skin Care & Cosmetics — Merger or Acquisition (March 2023)
199 slides from Flowerkist Skin Care & Cosmetics's merger presentation, Mar 22, 2023
Slide 1: Asset Purchase Agreement
ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) sets forth the principal terms on which ProVEDA Corporation (“ProVEDA”) and Flowerkist, Inc. (“Elowerkist”) have agreed with respect to the purchase (the “Transaction”) by ProVEDA from Flowerkist of all of Flowerkist’s assets
Slide 2: Change of Control, Warrant and License to Transdermal Delivery System
(ii) are referred to as a “Change of Control Transaction”). If, as of the date of the consummation of a Change of Control Transaction, the aggregate Purchase Price and Revenue Share payments received by Flowerkist are less than $10,000,000, then ProVEDA shall pay to Flowerkist contemporaneously with
Slide 3: Non-compete, Expenses and Miscellaneous
During the period beginning on the Signing Date and ending on the second (2nd) anniversary of the Initial Payment Deadline, Flowerkist shall not, and shall not allow any of its affiliates to, engage (whether as an owner, operator, manager, employee, officer, director, consultant, advisor, representa
Slide 4: Signature and Termination Terms
If the foregoing accurately reflects the basic terms and conditions of ProVEDA’s and Flowerkist’s agreement with respect to the Transaction, please sign and date one copy of this Agreement and return it to the undersigned. If this Agreement is fully executed, this Agreement shall remain in full forc
Slide 5: Schedule: Purchased Assets
Schedule 1 Purchased Assets (1) ProVEDA is acquiring the exclusive rights to all products associated with the wellness and therapeutic categories with regard to CBD enhanced topical solutions including but not limited to the products currently developed and referred to as Pain Management and Hand &
Slide 6: Development of Polyherbal Cannabis Based Products
DABUR Bivins —_ FOUNDATION = = Development of rationally designed polyherbal Cannabis based products with different therapeutic benefits Study data Version 1.1 16 March 2020 DABUR RESEARCH FOUNDATION 22, Site IV, Sahibabad Ghaziabad, U.P. 201010 INDIA www.daburresearch.in Confidential
Slide 7: Therapeutic Areas
me, \DABUR | RESEARCH — =~ —— = FOUNDATION =m i a Therapeutic areas Pain management Skin care Hand and foot care
Slide 8: Our Strategy
oes Our Strategy ft Rational selection of ingredients VY la NX Formulation development: Topical > S Extensive preclinical tests for efficacy and mechanism {- XN Permeability, penetration and safety tests y, (~ XN Formulation characterization ~ S * Knowledge and target based selection of ingredients
Slide 9: Product Map
ProductMap \ | J DABUR RESEARCH FOUNDATION = Formulation prototypes { Efficacy and \ permeability ormulation studies L: | In vitro efficacy tests | Lyi Skin permeability in vitro Efficacy in vitro } ( Permeability in vitro } ( Specifications and CoA } Comparator studies in vitro [ Rational selection
Slide 10: CBD Sources
= CBD sources a DABUR RCH FOUNDATION Concentrate \Sample Identification 1006 Laboratory Number 2019008857 Batch Number NA Matrix Concentrate [Analyzed Date 04/23/19 Extraction Date 04/23/19 %o mg/g 0.54% 5.43 ND ND 0.60% 5.98 59.70% 596.96 ND ND 1.34% 13.37 ND ND 1.81% 18.10 ND ND Delta 8-THC ND ND
Slide 11: CBD Technology
CBD Technology DABUR RESEARCH FOUNDATION =m
Slide 12: CBD Technology Ingredients and Methodology
a CBD technology ingredients and methodology , INGREDIENTS > Cholesterol Precirol ATO Span 60 Basil oil Eucalyptus oil Menthol CBD concentrate CBD Isolate Phospholipid PEG 400 PG Transcutol P Tween 80 Ks me, |DABUR ——<—in METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Sp
Slide 13: Optimization and Characterization
Optimization and Characterization DABUR RESEARCH FOUNDATION =m
Slide 14: Optimization by Using Design Expert
Optimization by using design expert Design of experiments (DOE) is a statistical technique for quickly optimizing performance of systems with known input variables. It starts with a screening experimental design test plan involving all the known factors that are suspected to affect the system's perf
Slide 15: Optimization by Using Design Expert
Optimization by using design expert eae, \DABUR — SS [RESEARCH = — JFOUNDATION i Factors Level | Low Level | High Level | Std. Dev. | Coding 0.0000) Actual 0.0000) Actual 20.00 0.0000 Actual Factor Name A LIPID CONCENTRATION 0.2000 0.1000 0.3000 B SURFACTANT CINCENTRATION 38.00 6.00 10.00 c HOMOGENI
Slide 16: Optimization Contour Plots
= )DABUR SS |RESEARCH OUNDATION a Optimization by using design expert- Contour plots — Contour plots showing simultaneous influence of independent variables on response parameters: (A) particle size, (B) zeta potential and (C) PDI of the formulated CBD technology within Box—Behnken experimental desi
Slide 17: Linear Correlation Plots Actual vs Predicted
me, |DABUR SS RESEARCH FOUNDATION a Linear correlation plots between actual and predicted values — ‘ETASIEE Fredited ys Actual Presiced vs. eral Coot sorts by vu of EAszE 1937 2257 * Figure 1 shows the linear plot between actual and predicted values and the corresponding residual plots for Zeta Size
Slide 18: Technology Characterization: Particle Size Determination
me, |DABUR ae . . oa SS RESEARCH Technology characterization — Particle size determination J FOUNDATION Zeta Size analysis is done by dynamic light scattering technique which measures the size of the particles suspended in a_ liquid. Particle size directly Malvern malvern ~W, Panalyticat ©, Banaiyti
Slide 19: Transmission Electron Microscopy
DABUR R RCH FOUNDATION a Technology Characterization- Transmission electron Microscopy — (cen is a technique in smn a high-energy electron beam created from an electron gun can strike a very thin sample. When the electron beam is transmitted through the sample an image is produced bearing the inform
Slide 20: Pain Management
Pain management DABUR RESEARCH FOUNDATION =m
Slide 21: Pain Management: Formulation Development
me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Formulation development
Slide 22: CBD Technology for Pain Cream and Roll On
a CBD technology for pain cream and roll on , INGREDIENTS > Cholesterol Precirol ATO Span 60 Basil oil Eucalyptus oil Menthol CBD concentrate CBD Isolate Phospholipid PEG 400 PG Transcutol P Tween 80 Ks me, |DABUR = | RESEARCH METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, a
Slide 23: Rational Selection of Ingredients for Pain Cream and Roll On
Rational selection of ingredients for Pain cream and Roll on = —= | RESEARCH Common names Scientific names Uses CBD Technology Spearmint Oil Eucalyptus oil Peppermint oil Camphor Clove bud oil Thyme oil Capsicum oleoresin oil Lavender oil Rosemary oil Myrrh oil Ginger oil Orange Sweet oil Chamomile
Slide 24: Method of Preparation for Pain Cream
ESEARCH Formulation development METHOD OF PREPARATION FOR PAIN CREAM >> Phase A: Step 1: All the oil phase ingredients were taken in a beaker and were heated. Phase B: Step 2: Appropriate amount of the water extracts and the actives were dissolved in distilled water. Step 3: CBD technology was then
Slide 25: Efficacy and Permeability Assessments
me, \DABUR SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Efficacy and permeability assessments
Slide 26: Efficacy Tests In Vitro 1
Efficacy tests in vitro..1 Rationale * COX-2 is an enzyme responsible for inflammation and pain. Inhibition of COX-2 plays key role in analgesic action. ¢ CBD derivatives have been reported as selective COX-2 inhibitors. ¢ Hence, inhibitory effect of CBD containing Pain formulations on COX-2 activit
Slide 27: Efficacy Tests In Vitro 2: Pain Cream COX-2
DABUR RESEARCH FOUNDATION [am i me Efficacy tests in vitro..2 ( COX-2 inhibition in vitro > Pain Cream 100 2 30 87.8 90.8 2 oI 80 Hy Vv 70 < o 58.5, 5 £ a 47.1 2 } cr ©£t 40 2s g 30 20.5 = 20 = 48 x - Ee | oO 0.01 0.05 0.1 15 15 75 Pain Cream XX ~ yy Pain Cream demonstrated analgesic effect by in vi
Slide 28: Efficacy Tests In Vitro 3: Pain Roll-On COX-2
DABUR RESEARCH a — ——) FOUNDATION [a i a Efficacy tests in vitro..3 ia COX-2 inhibition in vitro > Pain Roll-on 100 | 92.0 > 84. $ 90 A g 80 71.0 Y= 70 xo 5 60 54.0 ge 50 c=} ee 0 37.4 zw 30 2 20) Bs = 77 oO 0.01, 0.05 0.1 15 15 75 Pain Roll-On {ug/ml) Pain Roll-On demonstrated analgesic effect by i
Slide 29: Analgesic Activity Using Rat Tail Flick Method 1
me, |DABUR SS RESEARCH FOUNDATION om Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..1 ~~~ Principle: The tail flick test is a thermal hyperalgesia test in which the tail of the animal is subjected to a heat source. Once the animal feels uncomfortable, removes
Slide 30: Analgesic Activity Using Rat Tail Flick Method 2
Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..2 ( ae, )DABUR Tail Flick Reaction Time in Seconds GROUPS Omin | 30 min | 60 min | 120 min|240 min 15.3 a5e7) 15.6 15.4 15.2 Placebo, 200mg 0.56 0.34 0.49 0.45 0.66 15.0 29.3 27.3 23.5 19.0 Roll On, 200mg 0.62 3.0
Slide 31: Analgesic Activity Using Rat Tail Flick Method 3
mam Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..3 % Analgesic Activity (Rat Tail Flick Model) Roll On, 200mg Pain Cream, 200mg = 30min 120 min 240 min me, |DABUR | RESEARCH FOUNDATION * Topical application with “Roll on” cream demonstrated significant (p<0.
Slide 32: Permeability Tests In Vitro 1
Permeability tests in vitro..1 * Rationale * Evaluation of permeation for transdermal or topical formulations, for which the drug is released through the skin, is critical to establish bioavailability and thereby make an approximation of the effectiveness. Additionally, it is important to test perfo
Slide 33: Permeability Tests In Vitro 2
— eos S= — Pp A ‘ 5 — JFOUNDATION = ermeability tests in vitro..2 | y nl Results = Pain cream 62 (Innovator) £ 250.00 EY pga ic *« CBD cumulative permeation profile from TDDS is shown in ree i inst ti 3 450.00 figure (permeated amount plotted against time) ® 100.00 * Total CBD amount (yg + SD) perme
Slide 34: Permeability Tests In Vitro 3
me, |DABUR = | RESEARCH -—=~ = — JFOUNDATION = i a Permeability tests in vitro..3 * In-vitro permeation experiments reveals that, higher concentrations of CBD (240 ng/ml) was achieved in * Interpretation receptor solution (which is indicative of systemic circulation) at very initial time interval (1
Slide 35: Penetration Ex Vivo: Rat Skin
(conto Imaging: contoeat es using this technique. yy Penetration ex vivo — Rat skin microscopy is a powerful tool for generating high-resolution images and 3-D reconstructions of a specimen. This technique is used to investigate topical formulations for both penetration & penetration depth in vitro
Slide 36: Penetration Ex Vivo: Guinea Pig Skin
Penetration ex vivo — Guinea pig skin = A. Pain cream 6+2 (guinea pig) Depth 330m B. Charlotte's web (guinea pig) Depth 150um C. CBD Medic (guinea pig) Depth 135um pb. Myaderm ( guinea pig) onoentn 60ym Result: Confocal microscopy of guinea pig skin with z-stack (penetration depth profile) image at
Slide 37: Formulation Characterization
me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Formulation characterization
Slide 38: Formulation Characterization
Formulation Characterization ( PHYSICOCHEMICAL > PROPERTY: > Description: Light brown colour soft mass. > Solubility: Soluble in water > pH :-4.75 > Foreign Matter Passes the test. > Total Ash: 0.37 % w/w qe Viscosity at 25°C: 48333 i, ( HEAVY METAL > Lead: Below quantification limit Cadmium: Below
Slide 39: HPLC Method for CBD Content
kes R ——, SSS RESEARCH sam HPLC Method for CBD content IE * Flowrate -1 ml/min * Mobile phase - Channel A - (0.1% formic acid in ACN),Channel B — (0.1% Formic acid In Water) * — Injection volume - 25 ul * Column temperature - 50 °C * Detector wavelength - 230 nm * Runtime - 18 min * Column - Inertis
Slide 40: HPLC Analysis for CBD Content for Pain Cream
omy HPLC analysis for CBD content for Pain cream DARN ASIO=2904 Rsiaatt me, |DABUR SS RESEARCH FOUNDATION Chromatogram Of CBD Standard 4004 3507 3004 Signal; DAD1A,Sig=230,4 Ref= P| Name — RT {min Area 150. 14,82 4544.24 100: 50: Sum 4544 2066 o- i rr ee Ce Tinve (min) Chromatogram Of PAIN 6+2 DADA
Slide 41: Texture Analysis
Texture Analysis DABUR SEARCH FOUNDATION oa i m eit P| 1 A 4 } i “ a Pain Cream Sample Pain Cream Reference sample Pain Cream comparison sample vs Reference sample Results: Test iD Firmness Stickiness Work of shear Index of viscosity ‘3 3 g-sec g-sec Pain cream reference pain cream Dabur Peak Positi
Slide 42: Stability - Ongoing
me, |DABUR RESEARCH = JFOUNDATIN i === Stability - Ongoing = Stability of Pain Cream Batch No. DRF-FD/| ~~ 001- Stability Date 17-Dec-19 Mfg Date 11-Dec-19 Accelerated condition Intermediate condition Real Time condition 40°C/75% 302C/65% 252C/60% S.No. | Characterization | Initial 1M 3M 6M 3M 6M 9M
Slide 43: Safety Assessment
me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Safety assessment
Slide 44: Safety Tests In Vitro: Skin Irritation Using Human Reconstructed Skin
Safety tests in vitro — skin irritation using human reconstructed skin Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing,
Slide 45: Skin Irritation Using 3-D Skin: Pain Cream
me, |DABUR SS} RESEARCH FOUNDATION Safety tests in vitro — skin irritation using 3-D skin — Pain Cream = y 8 i (— Pain Cream >) 110 100 100 LL in a te ih 90 2 80 go” © 2 60 3 & 50 -- Peer eeee. eee 3 — 40 - 30 20 7.8 10 5 PF NC (Untreated) Pc (SDS) Pain Cream \ y, Pain Cream demonstrated 48.5% tissu
Slide 46: Skin Irritation Using 3-D Skin: Pain Roll-On
Safety tests in vitro — skin irritation using 3-D skin — Pain Roll-On P \ Tissue viability (wrt NC) 110 100 Qu8 © eeo6o6 50 20 10 “roo Pain Roll-On NC (Untreated) —_ - = a 78 P| PC (SDS) Pain Roll-On wy me, |DABUR a | RESEARCH -—=~ — — JFOUNDATION = i Pain Roll-On demonstrated 48% tissue viability i
Slide 47: Ocular Irritation HET-CAM
= | RESEARCH = es R ey ~~ Jrounpation = Safety tests in vitro — ocular irritation-HET-CAM —— Rationale + Assessment of ocular irritant potential Pain y } Cream 62 performed using HET-CAM (Hen's Egg es on An) im Test - Chorioallantoic Membrane) assay in { Ay accordance with INVITTOX n°96. \ \ \ = ~wS
Slide 48: Ocular Irritation HET-CAM: Pain Cream
me, |DABUR ——— RCH FOUNDATION = Safety tests in vitro — ocular irritation-HET—CAM - Pain Cream = CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS 0ee@ CAMs reaction Pain Cream 62 3 min exposure 30 sec exposure (Collective Score 16) (Collective Score 14) gq: © <= CAMs treated with t
Slide 49: Ocular Irritation HET-CAM: Pain Roll On
e PABUR —— RCH Safety tests in vitro — Ocular irritation-HET-CAM - Pain Roll On FOUNDATION CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >») é a A [ CAMs reaction Pain Roll On 62 3 min exposure 30 sec exposure (Collective Score 14) (Collective Score 13) Comer] Came] ae) Cae) / C
Slide 50: Comparators
Comparators Test product CBD content In vitro COX inhibition 1C50 (ug/ml) In vivo efficacy (% Analgesic activity) Permeation in vitro Flux (ug/(cm?"hr) —= JFOUNDATION = penetration ex vivo (guinea Pain Cream Pain Roll-On Myaderm Tl vs comparator Charlotte's web Tl vs comparator CBD Medic Tl vs compa
Slide 51: Product Claims and Attributes
DABUR RESEARCH FOUNDATION [am 7 =a : . a Product Claims and attributes a Good flux rate indicating permeation of higher CBD content across Permeability i skin XY a Efficacy in vitro f Good analgesic effect by inhibition of COX-2 activity | XY uy a a Efficacy in vivo | Good analgesic effect by pain r
Slide 52: Skin Health
Skin health DABUR RESEARCH FOUNDATION =m
Slide 53: Day Cream
Day Cream DABUR RESEARCH FOUNDATION =m
Slide 54: CBD Technology for Antiaging Day Cream
CBD TECHNOLOGY FOR ANTIAGING DAY CREAM Va INGREDIENTS ~ Cholesterol Precirol ATO Span 60 CBD concentrate CBD Isolate PEG 400 PG Transcutol P Tween 80 Water XN me, |DABUR SS RESEARCH METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Span 60 were taken and heated until the co
Slide 55: Rational Selection of Ingredients for Day Cream
Rational selection of ingredients for Day Cream = —= —- DABUR | RESEARCH Common names Scientific names USES CBD Technology - has good anti-inflammatory property Titanium Dioxide - Acts as a mineral UV filter Ginseng water extract Panax ginseng Stimulates skin metabolism by removing free radical from
Slide 56: Manufacturing Procedure of Day Cream
me, |DABUR = RESEARCH = JFOUNDATION = i Formulation development MANUFACTURING PROCEDURE OF DAY CREAM Step 1: All the water phase ingredients were accurately weighed and dissolved in half the amount of distilled Phase A: water and slightly heated for completely dissolution. Step 2: To this mixture ge
Slide 57: Efficacy Tests In Vitro
Efficacy tests in vitro Rationale ¢ Fibroblasts are key cells that contribute to a healthy skin. Their turnover, secretion of ECM (collagen, elastin, HA) maintains the skin health. Study design * Test Item was dissolved in DMSO to prepare stock solution. * The stock was diluted to achieve final test
Slide 58: Fibroblasts Proliferation and Collagen Synthesis
me, \DABUR => | RESEARCH FOUNDATION Efficacy tests in vitro — Fibroblasts proliferation 28 466 ae F 4 0 r 001 oot nooo. oa % Increase in fibroblasts proliferation (wrt Untreated) 6 8 886 8 8 ‘Anti-aging Day Cream (ug/ml) Collagen Boas z 5 eo 581 BE os azo éz 0 £2 x0 12 2 £ 10 ® 0 8.00001 o.oo oon An
Slide 59: Formulation Characterization
= |DABUR S| RESEARCH — (= JFOUNDATION = = > ( MICROBIAL CONTAMINATION: Formulation Characterization ( PHYSICOCHEMICAL > PROPERTY: > Description: Off white colour » Total Bacterial count, cfu/g.: alt HESS Less than 10 nee > Total fungal count,cfu/g: Less > Solubility: Soluble in water than 10 » pH :-
Slide 60: HPLC Analysis for CBD Content for Day Cream
— ee )DABUR Bivins = JFOUNDATION = mm HPLC analysis for CBD content for Day cream — DADIASY=204 REIDR Chromatogram Of CBD Standard mi 400- 3504 Signal: DAD1A,Sig=230,4 Ref= 3004 Name = - RT (rie) Aroa gor 150: 14,86 5089,23 ed sum 5089,2323 ts 50° . ae 1 7 a 4 5 6 7 5 8 10 n w 13 “4 16 16 v7 aL Tine
Slide 61: Safety Tests In Vitro: Skin Irritation Using 3-D Skin
Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing, tissues were allowed to recover for 24h. * Viability of tissue was dete
Slide 62: Skin Irritation Using 3-D Skin: Day Cream
me, |DABUR = | RESEARCH = FOUNDATION =m i === Safety tests in vitro — skin irritation using 3-D skin SS >» ( Anti-aging Day Cream » Rationale to a _ _ ¢ Assessment of viability in 3- 90 D reconstructed skin is used zB 0 to determine the skin 3 8 ew irritation potential in vitro gy g o , re ni (OECD4
Slide 63: Safety Tests In Vitro: Ocular Irritation HET-CAM
Safety tests in vitro — ocular irritation-HET—CAM Rationale + Assessment of ocular irritant potential Pain Cream 62 performed using HET-CAM (Hen's Egg Test - Chorioallantoic Membrane) assay in accordance with INVITTOX n°96. Study design * Test Item was applied for 3 min followed by washing followed
Slide 64: Ocular Irritation HET-CAM: Day Cream
ee |DABUR SS} RESEARCH FOUNDATION i CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >» Safety tests in vitro — Ocular irritation-HET-CAM CAMs reaction Antiaging Day Cream 3 min exposure | (Collective score 9) . Scoring:2 Scoring: 1 CAMs treated with the Anti-aging Day Cream for 3
Slide 65: Comparators
DABUR RESEARCH FOUNDATION = Comparators — CBD In vitro fibroblasts utyitro Comparator Test Item = : Collagen content proliferation : synthesis Anti-aging Day 2.20% w/v + 52.8% + 68.8% Cream Lord Jones + 43.9% + 61.9%
Slide 66: Product Claims and Attributes
DABUR RESEARCH FOUNDATION a Product Claims and attributes —
Slide 67: Night Cream
Night Cream DABUR RESEARCH FOUNDATION =m
Slide 68: CBD Technology for Night Cream
eae, \DABUR > eseancu CBD TECHNOLOGY FOR NIGHT CREAM “oN i METHODOLOGY ( » Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Span 60 were taken and INGREDIENTS heated until the content gets melted. Cholesterol . Drug Phase Precirol ATO > CBD concentrate and isolate were dissolved in pr
Slide 69: Rational Selection of Ingredients for Night Cream
Rational selection of ingredients for Night cream = —= DABUR | RESEARCH FOUNDATION =m Common Names Scientific names USES CBD Technology Elage Ginseng water extract Acacia berry water extract Guggul water extract Curcumin water extract Grapeseed water extract Manjishtha water extract Pomegranate wate
Slide 70: Manufacturing Procedure of Night Cream
me, |DABUR RESEARCH = — = JFOUNDATION = Formulation development MANUFACTURING PROCEDURE OF NIGHT CREAM Phase A: Step 1: All the water phase ingredients and actives were accurately weighed and dissolved in distilled water and slightly heated for completely dissolution. Step 2: To this mixture gelling
Slide 71: Efficacy Tests In Vitro
Efficacy tests in vitro Rationale ¢ Fibroblasts are key cells that contribute to a healthy skin. Their turnover, secretion of ECM (collagen, elastin, HA) maintains the skin health. Study design * Test Item was dissolved in DMSO to prepare stock solution. * The stock was diluted to achieve final test
Slide 72: Efficacy Tests In Vitro
Efficacy tests in vitro Fibroblasts proliferation 26 a2 252 L - 0 |_| 2 onoo01 oor 003 on % Increase in fibroblasts proliferation (wrt Untreated) 5B B88 8B Anti-aging Night Cream Ge/m)) Collagen Hi = 787 - @ fs ™ 9 gg 2 os Zi 9 85 « fz 25 2 2 2 wo & o 000. oo. oot ‘Anti-aging Night Cream (he/ml) = D
Slide 73: Formulation Characterization
Formulation Characterization (— PHYSICOCHEMICAL > PROPERTY: > Description: Off white colour soft mass. > Solubility: Soluble in water > pH :- 4.82 > Foreign Matter Passes the test. > Total Ash: 0.20 % w/w q ye Viscosity at 25°C: 43333 a, HEAVY METAL , Lead: Below quantification limit Cadmium: Below
Slide 74: HPLC Analysis for CBD Content for Night Cream
HPLC analysis for CBD content for Night cream Chromatogram Of CBD Standard Signal: VWD14,Wavel Name RT (min) | Area 7 14.55 4697.39 Sum 4697.29 — | 7 Chromatogram Of Night cream Signal: VWDI1A,Wavel Name RT (min) [Ares 14.84 2291,68 Sum 2281.67 59 VWD 1A Wavilengit=236 ni FOUNDATION [am i tf st Ser
Slide 75: Texture Analysis
Texture Analysis Force ig) ° re eee © © : ©. ° = ” | Sama y : ee j 2 Tine ee) al i, © = “2 oa “o Night Cream Sample Night Cream Reference sample Night Cream comparison sample vs Reference sample Results: Test ID Firmness Stickiness Work of shear Index of viscosity & c- g-sec g.sec Peak Positive Forc
Slide 76: Stability - Ongoing
Stability - Ongoing me, |DABUR SS RESEARCH FOUNDATION Stability of Night Cream Batch No. DRF-FD/AAN5-CBD/001-19 Stability Date | 18-Dec-19 Mfg Date 18-Dec-19 Characterizat S.No. ion Initial 402C/75% 302C/65% 252C/60% 1M 3M 6M 3M 6M OM 3M 6M 9M 12M Off [white Description |colour por 18-Jan-20 . 18-Ma
Slide 77: Safety Tests In Vitro: Skin Irritation Using 3-D Skin
Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing, tissues were allowed to recover for 24h. * Viability of tissue was dete
Slide 78: Skin Irritation Using 3-D Skin: Night Cream
Safety tests in vitro — skin irritation using 3-D skin ee |DABUR Sa | RESEARCH -s~ — = JFOUNDATION = Bi ia XN Tissue viability {wrt NC) Anti-aging Night Cream 100 NC (Untreated) PC (SDS) 102.7 Antiaging Night cream ~ y, Anti-aging Night Cream demonstrated 102.7% tissue viability in 3-D reconstructed
Slide 79: Safety Tests In Vitro: Ocular Irritation HET-CAM
Safety tests in vitro — ocular irritation-HET—CAM Rationale + Assessment of ocular irritant potential Pain Cream 62 performed using HET-CAM (Hen's Egg Test - Chorioallantoic Membrane) assay in accordance with INVITTOX n°96. Study design * Test Item was applied for 3 min followed by washing followed
Slide 80: Ocular Irritation HET-CAM: Night Cream
me, |DABUR | RESEARCH FOUNDATION a Safety tests in vitro — Ocular irritation-HET-CAM ( CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >» ~ CAMs reaction Antiaging Night Cream 3 min exposure (Collective score 7) a Scoring: 1 Scoring:2 CAMs treated with the Anti-aging Night Cream f
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: Slide 98
Slide 99: Slide 99
Slide 100: Slide 100
Slide 101: Slide 101
Slide 102: Slide 102
Slide 103: Slide 103
Slide 104: Slide 104
Slide 105: Slide 105
Slide 106: Slide 106
Slide 107: Slide 107
Slide 108: Slide 108
Slide 109: Slide 109
Slide 110: Slide 110
Slide 111: Slide 111
Slide 112: Slide 112
Slide 113: Slide 113
Slide 114: Slide 114
Slide 115: Slide 115
Slide 116: Slide 116
Slide 117: Slide 117
Slide 118: Slide 118
Slide 119: Slide 119
Slide 120: Slide 120
Slide 121: Slide 121
Slide 122: Slide 122
Slide 123: Slide 123
Slide 124: Slide 124
Slide 125: Slide 125
Slide 126: Slide 126
Slide 127: Slide 127
Slide 128: Slide 128
Slide 129: Slide 129
Slide 130: Slide 130
Slide 131: Slide 131
Slide 132: Slide 132
Slide 133: Slide 133
Slide 134: Slide 134
Slide 135: Slide 135
Slide 136: Slide 136
Slide 137: Slide 137
Slide 138: Slide 138
Slide 139: Slide 139
Slide 140: Slide 140
Slide 141: Slide 141
Slide 142: Slide 142
Slide 143: Slide 143
Slide 144: Slide 144
Slide 145: Slide 145
Slide 146: Slide 146
Slide 147: Slide 147
Slide 148: Slide 148
Slide 149: Slide 149
Slide 150: Slide 150
Slide 151: Slide 151
Slide 152: Slide 152
Slide 153: Slide 153
Slide 154: Slide 154
Slide 155: Slide 155
Slide 156: Slide 156
Slide 157: Slide 157
Slide 158: Slide 158
Slide 159: Slide 159
Slide 160: Slide 160
Slide 161: Slide 161
Slide 162: Slide 162
Slide 163: Slide 163
Slide 164: Slide 164
Slide 165: Slide 165
Slide 166: Slide 166
Slide 167: Slide 167
Slide 168: Slide 168
Slide 169: Slide 169
Slide 170: Slide 170
Slide 171: Slide 171
Slide 172: Slide 172
Slide 173: Slide 173
Slide 174: Slide 174
Slide 175: Slide 175
Slide 176: Slide 176
Slide 177: Slide 177
Slide 178: Slide 178
Slide 179: Slide 179
Slide 180: Slide 180
Slide 181: Slide 181
Slide 182: Slide 182
Slide 183: Slide 183
Slide 184: Slide 184
Slide 185: Slide 185
Slide 186: Slide 186
Slide 187: Slide 187
Slide 188: Slide 188
Slide 189: Slide 189
Slide 190: Slide 190
Slide 191: Slide 191
Slide 192: Slide 192
Slide 193: Slide 193
Slide 194: Slide 194
Slide 195: Slide 195
Slide 196: Slide 196
Slide 197: Slide 197
Slide 198: Slide 198
Slide 199: Slide 199
Flowerkist Skin Care & Cosmetics — Merger or Acquisition (March 2023) on 6ix